Clinical trial
Octreotide in Severe Polycystic Liver Disease
NCT00426153 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00426153 |
|---|---|
| Title | Octreotide in Severe Polycystic Liver Disease |
| Official title | Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | Novartis Industry National Center for Research Resources (NCRR) NIH |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain |
| Intervention type | Drug |
| Interventions | Octreotide, Placebo |
| Enrollment | 42 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 24, 2007 |
| Last update posted | Nov 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: